Cantor Fitzgerald L. P. Sells 2,000 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)

Cantor Fitzgerald L. P. reduced its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 10.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,000 shares of the biopharmaceutical company’s stock after selling 2,000 shares during the period. Cantor Fitzgerald L. P.’s holdings in Theravance Biopharma were worth $202,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TBPH. Principal Financial Group Inc. increased its stake in shares of Theravance Biopharma by 10.5% in the third quarter. Principal Financial Group Inc. now owns 18,637 shares of the biopharmaceutical company’s stock worth $161,000 after buying an additional 1,764 shares during the period. Dark Forest Capital Management LP bought a new position in shares of Theravance Biopharma during the third quarter valued at about $274,000. Newtyn Management LLC boosted its holdings in shares of Theravance Biopharma by 12.3% during the third quarter. Newtyn Management LLC now owns 1,841,560 shares of the biopharmaceutical company’s stock worth $15,893,000 after purchasing an additional 201,104 shares during the period. GSA Capital Partners LLP increased its holdings in Theravance Biopharma by 1,536.4% during the 3rd quarter. GSA Capital Partners LLP now owns 325,985 shares of the biopharmaceutical company’s stock valued at $2,813,000 after purchasing an additional 306,064 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its position in Theravance Biopharma by 324.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,759 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 4,402 shares during the last quarter. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Stock Performance

Shares of NASDAQ:TBPH opened at $8.64 on Thursday. The firm has a market capitalization of $420.16 million, a P/E ratio of -10.05 and a beta of 0.24. The stock has a 50 day moving average price of $9.11 and a 200-day moving average price of $9.51. Theravance Biopharma, Inc. has a 52-week low of $8.13 and a 52-week high of $11.71.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Monday, May 13th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.04. The company had revenue of $14.50 million for the quarter, compared to analysts’ expectations of $14.54 million. Theravance Biopharma had a negative return on equity of 18.97% and a negative net margin of 72.79%. On average, equities analysts forecast that Theravance Biopharma, Inc. will post -0.42 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TBPH has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Theravance Biopharma in a research report on Wednesday, May 29th. StockNews.com cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Thursday. Finally, BTIG Research initiated coverage on shares of Theravance Biopharma in a report on Friday, April 12th. They issued a “buy” rating and a $21.00 price objective for the company.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.